Trial Profile
Study of Pomalidomide in Anal Cancer Precursors (SPACE): a Phase 2 Study of Immunomodulation in People With Persistent HPV-associated High Grade Squamous Intraepithelial Lesions
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 Mar 2024
Price :
$35
*
At a glance
- Drugs Pomalidomide (Primary)
- Indications Cervical intraepithelial neoplasia
- Focus Therapeutic Use
- Acronyms SPACE
- 28 Mar 2022 Planned End Date changed from 31 Jan 2022 to 31 Dec 2022.
- 10 Oct 2021 Planned End Date changed from 1 Sep 2021 to 31 Jan 2022.
- 11 Mar 2020 Results assessing clearance of human papillomavirus anal high-grade intraepithelial lesions with low-dose pomalidomide, presented at the 27th Conference on Retroviruses and Opportunistic Infections